Stemtech Corp (STEK) Form 10-Q — Nov 13, 2026
Stemtech's 10-Q for the quarter ended September 30, 2026 carries going-concern language, with an accumulated deficit of $36.8 million, a working capital deficit of roughly $10.7 million, and just $255,555 in cash on hand. Nine-month net sales fell to $1.37 million from $2.42 million a year earlier, driven by distributor losses after product shortages in early 2026. Q3 revenue was $282,484 versus $852,300 in the prior-year quarter, though the quarterly net loss narrowed to $478,575 from $812,541 on cost cuts.
Key figures
- Eps
- -0.00 (basic and diluted, nine months FY2026)
- Revenue
- 1374753
- Total Debt
- 4544413
- Revenue Yoy
- -43.2% (nine months: $1,374,753 vs $2,418,271)
- Cash Position
- 255555
- Shares Outstanding
- 2997032856
- Current assets
- 558275
- Leviston funded
- 1561660
- Net loss q3 2025
- 812541
- Net loss q3 2026
- 478575
- Net sales q3 2025
- 852300
- Net sales q3 2026
- 282484
- Accumulated deficit
- 36809750
- Current liabilities
- 11221410
- Gross margin q3 2025
- 80.1%
- Gross margin q3 2026
- 75.6%
- Working capital deficit
- 10663135
- Channel partners advance
- 102000
- Interest expense q3 2025
- 508699
- Interest expense q3 2026
- 109526
- Leviston facility capacity
- 7000000
- Operating cash use 9m 2026
- 777119
- Convertible debt converted shares 9m 2026
- 2293909287
AI analysis
Red flags8 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.